Skip to main content

Day: August 23, 2023

Jaguar Global Growth Corporation I and GLAAM Provide Updates on Proposed Business Combination

Jaguar Global Shareholders Approve Extension of Deadline to Complete Initial Business Combination, with 44% of IPO Shares Still Outstanding Announce Appointees for the New Public Company, Captivision Inc., Board of Directors MIAMI and SEOUL, South Korea, Aug. 23, 2023 (GLOBE NEWSWIRE) — Jaguar Global Growth Corporation I (Nasdaq: JGGC, JGGCR, and JGGCW) (“Jaguar Global”) and GLAAM, Co., Ltd. (“GLAAM”), a leading designer and manufacturer of architectural media glass, today announced Jaguar Global shareholder approval of an extension to extend the date by which Jaguar Global has to consummate a business combination (the “Termination Date”) and appointees for the Board of Directors relating to the previously announced business combination. As a result of the business combination, GLAAM and Jaguar Global shareholders will exchange...

Continue reading

Halvårsrapport 2023 for Investeringsforeningen Nordea Invest

Bestyrelsen for Investeringsforeningen Nordea Invest har på bestyrelsesmøde den 23. august 2023 godkendt foreningens halvårsrapport for 1. halvår 2023. Halvårsrapporten for 2023 kan downloades på www.nordeafunds.com/da Med venlig hilsenNordea Fund Management, filial af Nordea Funds Oy, Finland Rasmus Eske Bruun Filialbestyrer

Continue reading

BlockQuarry Corp. Announces Completion of 2022 Annual Audit and Submission of OTCQB Application

HOUSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) — via IBN — BlockQuarry Corp. (OTC: BLQC) (“BlockQuarry” or the “Company”), a Texas-based company with commercial-stage operations in the energy and infrastructure industry, is pleased to announce completion of the 2022 annual audit and submission of its application to the OTCQB with the OTC Markets. The Company’s third-party auditing firm has completed its 2022 annual audit and will be posted shortly to OTC Markets. The audit confirms that 2022 was the best year for the Company in terms of revenue with an increase of over 500% in annual revenues compared to 2021 with revenues just shy of $6 million. Additionally, the company has submitted its application with the OTC Markets to be listed on the OTCQB tier. The application has been paid for and was received by OTC Markets and acknowledged;...

Continue reading

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on September 7, 2023. The outstanding shares of Series C Preferred Stock will vote together...

Continue reading

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise investment grade bonds. We believe that our existing cash, cash equivalents, other financial assets and marketable securities will be sufficient for...

Continue reading

Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is expected to be available for commercial use by licensed healthcare providers by September 2023 WEST CHESTER, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, issued a statement today in support of the U.S. Food and Drug Administration’s (“FDA’s”) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not...

Continue reading

Collective Metals Commences Phase Two Exploration Program for its Princeton Copper Project

Figure 1Figure 1VANCOUVER, British Columbia, Aug. 23, 2023 (GLOBE NEWSWIRE) — COLLECTIVE METALS INC. (CSE: COMT | OTC: CLLMF | FSE: TO1) (the “Company” or “Collective”) is pleased to announce commencement of their Phase Two Exploration Program (the “Program”) on its Princeton Copper Project (the “Project”). This Program is a regional reconnaissance soil program designed to evaluate 11 previously untested priority target areas across the Project. The smaller soil grids are intended as initial reconnaissance surveys, characterized by relatively widely spaced lines and a 75 m station interval. Anomalous results will be followed up with infill lines as required. Geochemical results from the soil grids are intended to further evaluate previously identified anomalies and complement existing data available for the Property, including...

Continue reading

Aurora Spine Corporation Announces Second Quarter Fiscal 2023 Financial Results

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICESManagement to host conference call for investors in coming week, details to follow –CARLSBAD, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the financial results for its second quarter fiscal 2023 ended June 30, 2023. All figures are in U.S. dollars. Financial and Business HighlightsIncrease in Sequential Revenues – Sales rose 21% in Q2 when compared to Q1 of 2023. Continued Strength in Zip Sales – Sales of the ZIP™ line of implants continued to be strong, with sales increasing by 32.6% in Q2 2023 over Q2 2022. Improved Product Mix –...

Continue reading

Aehr Test Systems to Participate in the Jefferies Semiconductor, IT Hardware & Communications Technology Summit on August 29, 2023

FREMONT, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) — Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced that it will participate in the Jefferies Semiconductor, IT Hardware & Communications Technology Summit taking place August 29-30, 2023 at the Four Seasons Hotel in Chicago. President and CEO Gayn Erickson and CFO Chris Siu will be hosting meetings with investors throughout the day on Tuesday, August 29.  “We look forward to discussing our unique semiconductor production test and burn-in solutions and the markets they serve with investors and shareholders at the Jefferies conference,” said Gayn Erickson, President and CEO of Aehr Test Systems. “Aehr Test provides complete production solutions for improving quality, reliability, and yield of semiconductors such...

Continue reading

Global Cannula Market Size to Reach USD 334.7 Million in 2032 | Emergen Research

Increase in prevalence of chronic diseases is a major factor driving the market revenue growth Vancouver, Aug. 23, 2023 (GLOBE NEWSWIRE) — The global cannula market, valued at USD 167.8 Million in 2022, is projected to exhibit a revenue Compound Annual Growth Rate (CAGR) of 7.1% throughout the forecast period, as per the latest analysis conducted by Emergen Research. The market’s upward trajectory is primarily propelled by the escalating prevalence of surgical procedures. Notably, the Aesthetic Society’s data indicates a substantial surge in attractive body-related surgeries such as liposuction, buttock augmentation, and abdominoplasty, marking a notable 63% increase since 2020. Plastic surgeons, on average, performed 320 surgical procedures in 2021, marking a significant rise from the 220 procedures conducted in 2020....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.